Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Sodium calcium edetate + tobramycin by Respirion Pharmaceuticals for Pseudomonas aeruginosa Infections: Likelihood of Approval
Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Pseudomonas aeruginosa...
Data Insights
Sodium calcium edetate + tobramycin by Respirion Pharmaceuticals for Cystic Fibrosis: Likelihood of Approval
Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Cystic Fibrosis....